Reviewing Treatment Options for Cardiac Amyloidosis-3. Reviewing Treatment Options for Cardiac Amyloidosis with the CV Care Team

3. Reviewing Treatment Options for Cardiac Amyloidosis with the CV Care Team

Video Transcription

Video Summary

The discussion on cardiac amyloidosis explored the condition's pathology, diagnosis, and treatment. Cardiac amyloidosis is characterized by protein deposits in the heart, causing thickening and stiffening, ultimately leading to heart failure symptoms. Diagnosis requires identifying protein origins (AL amyloidosis from immunoglobulin light chains and TTR amyloidosis from the transthyratin protein) through specific lab tests. Treatment involves collaboration between cardiologists and hematologists, particularly for TTR forms, using stabilizers to prevent protein degradation and potential new therapies like vutricerin. Nurse practitioners, like Janelle Grazzini-France, play a crucial role in patient education and follow-up care, while pharmacists, like Dan Landup, assist in managing drug interactions and navigating prescription processes. The evolving therapeutic landscape, including drugs like tefamidus and acaramidus, alongside potential new treatments, represents hope despite challenges in managing this complex disease.

Keywords

cardiac amyloidosis

restrictive cardiomyopathy

immunoglobulin light chains

transthyretin protein

heart failure symptoms

protein deposits

diagnosis

treatment

therapeutic landscape